| Acumen Pharmaceuticals is engaged in the discovery and development of targeted therapies for the treatment of Alzheimer's disease ("AD"). Co.'s lead drug candidate, ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic models for ADs. Co. and Merck & Co. discovered and developed ACU193 through an eight-year research collaboration. Co. holds exclusive rights to the program. Co. submitted an Investigation Drug Application for ACU193 to the Food and Drug Administration. We show 1 historical shares outstanding datapoints in our ABOS shares outstanding history coverage, used to compute ABOS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABOS market cap history over the course of time is important for investors
interested in comparing ABOS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABOS versus a peer is one thing; comparing
ABOS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABOS can fluctuate over the course of history.
With this page we aim to empower investors researching ABOS by allowing them to research the ABOS market cap history.